logo-loader
RNS
CVS Group

CVS Group plc - Transaction in Own Shares

RNS Number : 8349L
CVS Group plc
17 December 2025
 

17 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 16 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

 

Date of purchase:

16/12/2025

Aggregate number of Ordinary Shares purchased:

4,432

Lowest price paid per share (GBp):

1,228.00

Highest price paid per share (GBp):

1,248.00

Volume weighted average price paid per share (GBp):

1,240.57


CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,821,122 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,821,122 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 919,661 Ordinary Shares in aggregate at a weighted average price of 1,216.05 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

 

Individual transactions:

 

Number of

Ordinary Shares purchased

Transaction price (GBp share)

Time of

transaction (UK Time)

Transaction

reference number

Trading Venue

 


237

1228

16/12/2025 08:27:01

1352700633551196

XLON


630

1230

16/12/2025 11:21:09

1352700633561715

XLON


636

1236

16/12/2025 13:53:15

1352700633570871

XLON


474

1242

16/12/2025 14:26:54

1352700633573429

XLON


289

1242

16/12/2025 14:26:54

1352700633573436

XLON


93

1244

16/12/2025 14:59:42

1352700633578048

XLON


11

1244

16/12/2025 15:28:59

1352700633582307

XLON


143

1244

16/12/2025 15:38:33

1352700633583474

XLON


74

1244

16/12/2025 15:38:33

1352700633583476

XLON


13

1242

16/12/2025 15:56:59

1352700633586344

XLON


48

1242

16/12/2025 15:56:59

1352700633586345

XLON


137

1242

16/12/2025 15:56:59

1352700633586346

XLON


137

1242

16/12/2025 15:56:59

1352700633586347

XLON


26

1242

16/12/2025 15:56:59

1352700633586348

XLON


198

1242

16/12/2025 16:08:52

1352700633589090

XLON


35

1248

16/12/2025 16:27:25

1352700633593369

XLON


110

1248

16/12/2025 16:27:25

1352700633593368

XLON


6

1248

16/12/2025 16:27:25

1352700633593370

XLON


260

1248

16/12/2025 16:27:25

1352700633593372

XLON


83

1248

16/12/2025 16:27:25

1352700633593371

XLON


396

1248

16/12/2025 16:27:32

1352700633593429

XLON


198

1248

16/12/2025 16:27:32

1352700633593428

XLON


198

1248

16/12/2025 16:27:32

1352700633593430

XLON


 

 

Contacts

CVS Group plc                                                                                                                                                 via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker)                                                                                 +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint Broker)                                                                                                                             +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR)                                                                                                                             cvsg@camarco.co.uk

Ginny Pulbrook                                                                                                                                                +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSGPGUUPUPAGRQ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Transaction in Own Shares

3 days, 12 hours ago

Transaction in Own Shares

1 week, 3 days ago

Transaction in Own Shares

2 weeks, 3 days ago

Total Voting Rights

2 weeks, 6 days ago

Transaction in Own Shares

3 weeks, 3 days ago

4 min read